Progress towards gene therapy for cancer

C. Marchisone, U. Pfeffer, F. Del Grosso, D. M. Noonan, L. Santi, A. Albini

Research output: Contribution to journalArticle

Abstract

This review highlights the current strategies being employed towards gene therapy of cancer. Conceptually, the most simple diseases to treat with gene therapy would be monogenic inherited diseases, such as hemophilia. However, the vast majority of current gene therapy trials are for treatment of cancer patients, due to the recognition of gene alterations in cancer and the critical need for improvement of cancer therapy. Gene-based therapies for cancer in clinical trials include strategies that involve immuno-therapy, induction of drug sensitivity in tumor cells or resistance to chemotherapy of critical host tissues, and compensation for oncosuppressor loss or ablation of oncogenes. Two broad approaches have been used to deliver DNA to cells, a series of viral vectors and the use of plasmid DNA vectors, which have different advantages with regard to efficiency of gene transfer, ease of production and safety. Examined objectively, many of the first studies in cancer gene therapy clinical trials have provided information of critical importance for the design of more efficient second-generation protocols. Gene therapy represents one of the most important developments in oncology, however, before this can be realized as standard treatment the technical problems of gene delivery and safety must be overcome. Here we focus on methods and strategies used to achieve cancer gene therapy and the current clinical trials.

Original languageEnglish
Pages (from-to)261-270
Number of pages10
JournalJournal of Experimental and Clinical Cancer Research
Volume19
Issue number3
Publication statusPublished - 2000

Fingerprint

Genetic Therapy
Neoplasms
Neoplasm Genes
Clinical Trials
Genes
Safety
Drug Therapy
DNA
Hemophilia A
Oncogenes
Plasmids
Therapeutics

Keywords

  • Cancer
  • Clinical Trials
  • Gene Therapy
  • Immunotherapy
  • Vectors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Progress towards gene therapy for cancer. / Marchisone, C.; Pfeffer, U.; Del Grosso, F.; Noonan, D. M.; Santi, L.; Albini, A.

In: Journal of Experimental and Clinical Cancer Research, Vol. 19, No. 3, 2000, p. 261-270.

Research output: Contribution to journalArticle

@article{d634b82925004ea3abb57c74d70c90b0,
title = "Progress towards gene therapy for cancer",
abstract = "This review highlights the current strategies being employed towards gene therapy of cancer. Conceptually, the most simple diseases to treat with gene therapy would be monogenic inherited diseases, such as hemophilia. However, the vast majority of current gene therapy trials are for treatment of cancer patients, due to the recognition of gene alterations in cancer and the critical need for improvement of cancer therapy. Gene-based therapies for cancer in clinical trials include strategies that involve immuno-therapy, induction of drug sensitivity in tumor cells or resistance to chemotherapy of critical host tissues, and compensation for oncosuppressor loss or ablation of oncogenes. Two broad approaches have been used to deliver DNA to cells, a series of viral vectors and the use of plasmid DNA vectors, which have different advantages with regard to efficiency of gene transfer, ease of production and safety. Examined objectively, many of the first studies in cancer gene therapy clinical trials have provided information of critical importance for the design of more efficient second-generation protocols. Gene therapy represents one of the most important developments in oncology, however, before this can be realized as standard treatment the technical problems of gene delivery and safety must be overcome. Here we focus on methods and strategies used to achieve cancer gene therapy and the current clinical trials.",
keywords = "Cancer, Clinical Trials, Gene Therapy, Immunotherapy, Vectors",
author = "C. Marchisone and U. Pfeffer and {Del Grosso}, F. and Noonan, {D. M.} and L. Santi and A. Albini",
year = "2000",
language = "English",
volume = "19",
pages = "261--270",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "3",

}

TY - JOUR

T1 - Progress towards gene therapy for cancer

AU - Marchisone, C.

AU - Pfeffer, U.

AU - Del Grosso, F.

AU - Noonan, D. M.

AU - Santi, L.

AU - Albini, A.

PY - 2000

Y1 - 2000

N2 - This review highlights the current strategies being employed towards gene therapy of cancer. Conceptually, the most simple diseases to treat with gene therapy would be monogenic inherited diseases, such as hemophilia. However, the vast majority of current gene therapy trials are for treatment of cancer patients, due to the recognition of gene alterations in cancer and the critical need for improvement of cancer therapy. Gene-based therapies for cancer in clinical trials include strategies that involve immuno-therapy, induction of drug sensitivity in tumor cells or resistance to chemotherapy of critical host tissues, and compensation for oncosuppressor loss or ablation of oncogenes. Two broad approaches have been used to deliver DNA to cells, a series of viral vectors and the use of plasmid DNA vectors, which have different advantages with regard to efficiency of gene transfer, ease of production and safety. Examined objectively, many of the first studies in cancer gene therapy clinical trials have provided information of critical importance for the design of more efficient second-generation protocols. Gene therapy represents one of the most important developments in oncology, however, before this can be realized as standard treatment the technical problems of gene delivery and safety must be overcome. Here we focus on methods and strategies used to achieve cancer gene therapy and the current clinical trials.

AB - This review highlights the current strategies being employed towards gene therapy of cancer. Conceptually, the most simple diseases to treat with gene therapy would be monogenic inherited diseases, such as hemophilia. However, the vast majority of current gene therapy trials are for treatment of cancer patients, due to the recognition of gene alterations in cancer and the critical need for improvement of cancer therapy. Gene-based therapies for cancer in clinical trials include strategies that involve immuno-therapy, induction of drug sensitivity in tumor cells or resistance to chemotherapy of critical host tissues, and compensation for oncosuppressor loss or ablation of oncogenes. Two broad approaches have been used to deliver DNA to cells, a series of viral vectors and the use of plasmid DNA vectors, which have different advantages with regard to efficiency of gene transfer, ease of production and safety. Examined objectively, many of the first studies in cancer gene therapy clinical trials have provided information of critical importance for the design of more efficient second-generation protocols. Gene therapy represents one of the most important developments in oncology, however, before this can be realized as standard treatment the technical problems of gene delivery and safety must be overcome. Here we focus on methods and strategies used to achieve cancer gene therapy and the current clinical trials.

KW - Cancer

KW - Clinical Trials

KW - Gene Therapy

KW - Immunotherapy

KW - Vectors

UR - http://www.scopus.com/inward/record.url?scp=0033759086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033759086&partnerID=8YFLogxK

M3 - Article

C2 - 11144517

AN - SCOPUS:0033759086

VL - 19

SP - 261

EP - 270

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 3

ER -